Biote Corp.: financial analysis
Ratios worked out from 6 fiscal years of Biote Corp.'s statements, compared with 1,214 companies in Healthcare.
Biote Corp. scorecard#
Passes 16 of the 23 checks that could be worked out: strongest in financial health (4 of 4), weakest in valuation (3 of 6). Fiscal year 2025; market cap of Oct 13, 2026.
Valuation3 of 6
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Healthcare's median of 3.7×.
- ✓Free cash flow yield above 5%73.8%Free cash flow is 73.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- ✓The price assumes slower growth than the last three years'-16.8%The price assumes -16.8% a year for ten years; revenue grew 5.2% a year over the last three.
Growth2 of 4
- ✗Revenue grew in the newest year-2.5%Revenue down 2.5% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years5.2%5.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median5.2%5.2% a year against Healthcare's median of 8.5% (549 companies).
- ✓Earnings per share grew in the newest year0.74 vs 0.09Diluted EPS 0.74 in fiscal 2025 against 0.09 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability3 of 4
- ✓Profitable in the newest year$27 MNet income $27 M in fiscal 2025.
- ✗Profitable in each of the last five years4 of 5Profitable in 4 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median18.5%18.5% against Healthcare's median of -7.7% (674 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier18.5%18.5% in fiscal 2025 against -36.8% in 2022.
Financial health4 of 4
- ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.22 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✓Net debt below three years of EBITDA2.0×Net debt 2.0 times EBITDA in fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone2.50Z-score 2.50 (grey zone) for fiscal 2025.
Shareholder returns4 of 5
- ✓Pays a dividendYesPaid dividends in fiscal 2025.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- ✓Dividends under 75% of net income6.4%Dividends were 6.4% of net income in fiscal 2025.
- ✗Share count up no more than 2% in a year7.0%Diluted shares up 7.0% in fiscal 2025.
- ✓Dividends and buybacks above 3% of the market value12.4%Dividends and buybacks were 12.4% of the market value.
- ✓Free cash flow covers dividends and buybacks$30 MFree cash flow $30 M against $5 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Revenue fell 2.5% against the year before.
- The share count rose 7.0% in the year.
- Shareholders' equity is negative: -$59 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsno
- Current ratio roseno
- No new shares issuedno
- Gross margin rosenot on file
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.09 | × 1.2 | 0.11 |
| Retained earnings to assets | -0.46 | × 1.4 | -0.64 |
| Operating income to assets | 0.33 | × 3.3 | 1.09 |
| Market value to liabilities | 0.26 | × 0.6 | 0.16 |
| Revenue to assets | 1.79 | × 1 | 1.79 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 18.5% | 16.0% | 15.5% | -36.8% | 24.8% | -7.7% | 86% | |
| Net margin | 14.1% | 1.6% | 1.8% | -0.6% | 8.0% | -8.1% | 84% | |
| Return on equity | — | — | — | — | 536.7% | -36.9% | — | |
| Return on assets | 23.5% | 2.3% | 2.5% | -1.2% | 40.8% | -29.1% | 97% | |
| Return on invested capital | — | — | — | -274.6% | 95.3% | 11.2% | — |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -2.5% | 6.4% | 12.4% | 18.3% | — | 10.2% | 21% | |
| Revenue growth, 3 years a year | 5.2% | 12.3% | — | — | — | 8.5% | 42% | |
| Net income growth | 755.7% | -4.8% | — | — | — | 12.0% | 100% | |
| Earnings per share growth | 722.2% | -30.8% | — | — | — | 8.2% | 99% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | — | — | — | — | 7.76× | 0.45× | — | |
| Net debt | $79 M | $70 M | $27 M | $43 M | $32 M | $7 M | 37% | |
| Net debt to EBITDA | 2.01× | 1.99× | 0.84× | — | 0.89× | 1.78× | 48% | |
| Current ratio | 1.22× | 1.32× | 5.51× | 5.39× | 2.72× | 3.18× | 20% | |
| Equity share of assets | -54.4% | -86.6% | -18.9% | -39.8% | 7.6% | 55.7% | 9% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $30 M | $39 M | $27 M | $-9 M | $32 M | $-11 M | 76% | |
| Free cash flow margin | 15.7% | 19.7% | 14.3% | -5.8% | 23.2% | -1.3% | 82% | |
| Cash conversion | 130.1% | 1,431.7% | 809.6% | — | 303.5% | 147.6% | 42% | |
| Capital spending share of revenue | 2.6% | 3.3% | 0.2% | 0.2% | 1.0% | 2.3% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 1.67× | 1.42× | 1.39× | 1.99× | 5.12× | 0.53× | 94% |
How each figure is worked out#
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Return on invested capital
- Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Net debt to EBITDA
- Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Dividend yield
- Dividends paid in the fiscal year as a share of today's market value.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Dividend payout
- Dividends paid as a share of net income. Only when the year was profitable.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).